Company: NCEL
Filing Date: 2025-01-08
Form Type: 425
Source: 0001213900-25-001822
Chunk: 2

Company: NewcelX Ltd.
Filing Date: 2025-01-08
Form: 425
Chunk 2
---
 with product
candidates in advanced stages of clinical development.

Additionally, as previously announced, NLS recently filed an F-4 Registration
Statement with the U.S. Securities and Exchange Commission (SEC), outlining the details of a proposed merger with Kadimastem. The company
intends to convene an extraordinary general meeting to secure the necessary approvals for the merger as part of the closing process.

“With the successful completion of the
initial portion of the fundraising, we are further bolstering our capacity to complete the merger with Kadimastem, which we believe
will enhance our strategic position in the biotechnology sector,” stated Alex Zwyer, Chief Executive Officer of NLS.
“We are enthusiastic about the opportunities ahead and remain committed to delivering value to our shareholders and making a
significant impact in patient care.”

Ronen Twito, Executive Chairman and Chief Executive Officer of Kadimastem, stated, “The successful completion of this financing of NLS marks a significant advancement in our journey toward merging with
NLS Pharmaceutics. This funding not only demonstrates confidence in our strategic direction but also positions us to create a powerful
new entity in the biotechnology sector. We are excited about the enhanced opportunities this merger will unlock for our shareholders and
our commitment to advancing innovative therapies in cell therapy and neuroscience.”

About NLS Pharmaceutics Ltd.

NLS is a global development-stage biopharmaceutical
company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development
of innovative therapies for patients with rare and complex central nervous system disorders who have unmet medical needs. Headquartered
in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing
product candidates. For more information, please visit www.nlspharma.com.

About Kadimastem

Kadimastem is a clinical stage cell therapy company,
developing “off-the-shelf”, allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation
of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company’s lead product, is an astrocyte cell therapy
in clinical development for the treatment for ALS and in pre-clinical studies for other neurodegenerative indications.

IsletRx is the company’s treatment for diabetes.
IsletRx is comprised of functional pancreatic islet cells producing and releasing insulin and glucagon, intended to treat and potentially